Cue Biopharma CEO receives stock and option grants

Cue Biopharma CEO Shao-Lee Lin reported equity awards on Common Stock.

Rhea-AI Filing Summary

Cue Biopharma CEO Shao-Lee Lin reported equity awards on Common Stock. Lin received 327,537 shares of Common Stock and a stock option for 655,074 shares at an exercise price of $30.42 per share, vesting in 48 equal monthly installments beginning on April 30, 2026.

Insider Trade Summary

Grant/Award: 982,611 shares

Grant/Award 2 txns

Insider Lin Shao-Lee

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	655,074	$0.00	$0.00
Grant/Award	Common Stock	327,537	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 655,074 contracts (Direct); Common Stock — 327,537 shares (Direct)

Footnotes (1)

1. F1. This stock option becomes exercisable in 48 equal monthly installments beginning on April 30, 2026.

Key Figures

Common Stock grant: 327,537 shares Stock option grant: 655,074 options Option exercise price: $30.42 per share +4 more

7 metrics

Common Stock grant 327,537 shares Non-derivative A-code award on May 3, 2026; post-transaction holdings

Stock option grant 655,074 options Derivative A-code award on May 3, 2026; underlying Common Stock

Option exercise price $30.42 per share Conversion or exercise price for 655,074-share stock option

Option expiration May 2, 2036 Expiration date of stock option award

Vesting schedule 48 monthly installments Option becomes exercisable in 48 equal monthly installments from April 30, 2026

Common shares after grant 327,537 shares Total Common Stock directly held following the transaction

Derivative transactions count 1 derivative transaction One derivative A-code award reported in transaction summary

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, Common Stock, exercise price, +1 more

5 terms

Stock Option (right to buy) financial

"The security title is listed as “Stock Option (right to buy)”."

Grant, award, or other acquisition financial

"The transaction code description is “Grant, award, or other acquisition”."

Common Stock financial

"One transaction involves 327,537.0000 shares of Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercise price financial

"The option’s conversion or exercise price is reported as 30.4200."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

exercisable in 48 equal monthly installments financial

"This stock option becomes exercisable in 48 equal monthly installments beginning on April 30, 2026."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cue Biopharma (CUE) CEO Shao-Lee Lin report in this Form 4?

Shao-Lee Lin reported receiving equity awards from Cue Biopharma. The filing shows a grant of 327,537 shares of Common Stock and a stock option covering 655,074 shares, both coded as “grant, award, or other acquisition” transactions on May 3, 2026.

How many Cue Biopharma (CUE) shares does the CEO hold after this filing?

After the reported transaction, Shao-Lee Lin directly holds 327,537 shares of Cue Biopharma Common Stock. The Form 4 also shows a stock option for 655,074 underlying shares, providing additional potential future ownership if the option is exercised.

What are the key terms of the Cue Biopharma (CUE) stock option granted to the CEO?

The CEO received a stock option for 655,074 shares of Common Stock at an exercise price of $30.42 per share. According to the footnote, the option becomes exercisable in 48 equal monthly installments beginning on April 30, 2026, and expires on May 2, 2036.

Is the Cue Biopharma (CUE) CEO’s Form 4 transaction a market purchase or sale?

The Form 4 does not show any market purchases or sales. Both entries are coded as “A” transactions, described as “grant, award, or other acquisition,” indicating equity awards rather than open-market buying or selling of Cue Biopharma shares.

When do the newly granted Cue Biopharma (CUE) stock options start vesting for the CEO?

The footnote states the stock option becomes exercisable in 48 equal monthly installments beginning on April 30, 2026. This means vesting is spread monthly over four years from that date, subject to the option’s overall expiration on May 2, 2036.

What types of securities are included in the Cue Biopharma (CUE) CEO’s Form 4?

The filing includes two security types. One is Common Stock, representing 327,537 shares held directly. The other is a derivative security labeled “Stock Option (right to buy)” covering 655,074 underlying shares of Common Stock at a fixed exercise price of $30.42 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 04:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Shao-Lee

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/03/2026		A		327,537	A	$0	327,537	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$30.42	05/03/2026		A		655,074		(1)	05/02/2036	Common Stock	655,074	$0	655,074	D

Explanation of Responses:

1. This stock option becomes exercisable in 48 equal monthly installments beginning on April 30, 2026.

	/s/ Shao-Lee Lin	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)